Skip to main content

15 Result(s)

within J. P. Droz Remove this filter Medicine & Public Health Remove this filter

and

  1. No Access

    Chapter

    Effects of Treatment of Malignant Lymphomas on the Granulocytic Progenitor Cells (CFUc)

    Study of the after-effects of therapy on the healthy organs is one of the main preoccupations of oncology. Although progress in therapeutics has clearly improved the prognosis for malignant lymphomas, the afte...

    C. Parmentier, D. Maraninchi, N. Morardet, J. P. Droz… in Lymphoid Neoplasias II (1978)

  2. No Access

    Chapter

    First Results of a Randomized Trial on Immunotherapy of Head and Neck Tumors

    Trials of active nonspecific immunotherapy as adjuvant therapy for tumors have increased dramatically in number since the results that have been published on acute leukemia [6] and melanoma [3, 5, 7–9]. In spi...

    J. L. Amiel, H. Sancho-Garnier… in Adjuvant Therapies and Markers of Post-Sur… (1979)

  3. No Access

    Chapter and Conference Paper

    High-dose chemotherapy with hematologic rescue for high-risk non-seminomatous germ cell tumors

    Despite progress in the treatment of disseminated non-seminomatous germ cell tumors (NSGCT), 20–30%of patients do not achieve CR or relapse [1]. We evaluated high-dose chemotherapy (HDC) followed by autologous...

    J. L. Pico, J. P. Droz, E. Zambon… in Proceedings of the 3rd International Congr… (1991)

  4. No Access

    Article

    Phase II trial of pirarubicin in the treatment of advanced bladder cancer

    Doxorubicin is one of the standard drugs in the chemotherapy of advanced urothelial tumors. Pirarubicin, a new anthracycline, turned out to be equally active and less toxic than its parent compound in preclini...

    M. Mahjoubi, J. Kattan, M. Ghosn, J. -P. Droz, I. Philippot… in Investigational New Drugs (1992)

  5. No Access

    Chapter and Conference Paper

    No advantage for the use of an early high-dose chemotherapy with autologous bone marrow transplantation in first-line treatment of poor risk non-seminomatous germ cell tumors

    The results of the treatment of non-seminomatous germ cell tumors (NSGCT) have been dramatically improved by Cisplatin-based chemotherapy regimens and selective indication of surgery. Approximately 80 % of all...

    H. Curé, J. P. Droz, J. L. Pico, P. Biron, P. Kerbrat… in Cancer Treatment An Update (1994)

  6. No Access

    Article

    Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer

     Lanreotide (BIM 32014), a somatulin analogue, was found to be as effective as castration in a rat prostate tumor model. Therapeutic benefit was also demonstrated in the hormone-resistant phase of this tumor m...

    C. Maulard, J. P. Droz, D. Jessueld, M. Housset… in Cancer Chemotherapy and Pharmacology (1995)

  7. No Access

    Article

    Phase I–II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer

    Lanreotide (BIM 32014), a somatulin analogue, was found to be as effective as castration in a rat prostate tumor model. Therapeutic benefit was also demonstrated in the hormone-resistant phase of this tumor mo...

    C. Maulard, P. Richaud, J. P. Droz, D. Jessueld… in Cancer Chemotherapy and Pharmacology (1995)

  8. No Access

    Chapter

    Testicular tumors

    Tumors of the testicles, although relatively infrequent (less than 1% of cancers in males), are still used as a model for study in oncology, principally as a result of their curability by chemotherapy.

    E.-Ch. Antoine, J.-P. Droz, D. Buthiau in CT and MRI in Oncology (1998)

  9. No Access

    Article

    Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors

    Objective: To investigate the antitumor activity and the safety of RFS2000, an oral topoisomerase I inhibitor, in patients with advanced or metastatic urothelial tract tumors refractory to one prior chemotherapy...

    M.J.A. de Jonge, J.P. Droz, L. Paz-Ares, A.T. van Oosterom… in Investigational New Drugs (2004)

  10. No Access

    Chapter

    Traitement des formes de mauvais pronostic

    A. Fléchon, J.-P. Droz in Cancer du testicule (2006)

  11. No Access

    Article

    Réflexions sur l’organisation de l’oncogériatrie et rôle des réseaux

    Le réseau d’oncogériatrie devra comprendre toutes les personnes et toutes les structures qui gèrent la prise en charge clinique de la personne âgée atteinte de cancer à toutes les étapes de la maladie. Les out...

    J.-P. Droz, P. Courpron in Oncologie (2006)

  12. No Access

    Article

    Quelle évaluation gérontologique faut-il utiliser pour les essais multicentriques?

    Peu de personnes âgées atteintes de cancer sont incluses dans des essais cliniques. Ainsi, la connaissance sur l’efficacité et la tolérance des traitements est-elle médiocre dans cette population de patients. ...

    A. Chaladaj, C. Terret, G. Albrand, P. Courpron, J. -P. Droz in Oncologie (2007)

  13. No Access

    Article

    Motesanib difosfato nel cancro tiroideo differenziato progressivo

    PREMESSE: L’espressione del vascular endothelial growth factor (VEGF) è tipica dei carcinomi tiroidei differenziati ed è associata ad un comportamento aggressivo e ad una evoluzione sfavorevole. Il motesanib difo...

    S. I. Sherman, L. J. Wirth, J. P. Droz, M. Hofmann, L. Bastholt… in L’Endocrinologo (2008)

  14. No Access

    Chapter

    Cancer de la vessie/uretère

    Les tumeurs urothéliales sont des tumeurs fréquentes qui se développent aux dépens de l’arbre urinaire. Elles siègent le plus souvent dans la vessie mais elles peuvent aussi avoir comme origine le haut apparei...

    H. Boyle, A. Fléchon, J.-P. Droz in Thérapeutique du cancer (2011)

  15. No Access

    Chapter

    Cancer de la prostate

    L’adénocarcinome de prostate est un cancer extrêmement fréquent qui touche en particulier l’homme âgé. Il est en effet, le premier cancer de l’homme de plus de 70 ans en incidence mais le second pour la mortal...

    L. Mourey, J. -P. Droz in Oncogériatrie (2011)